


Supplementary Materials for Ilich et al. (TXA ineffective in absence of hyperfibrinolysis)

Supplementary Table 1.

		FEAT N=119	Non- FEAT N=211	p-value
Age	mean (sd)	53 (12.6)	54.5 (12.8)	0.36
Sex				
Male	n (%)	54 (45.4%)	84 (39.8%)	0.39
Female	n (%)	65 (54.6%)	127 (60.2%)	
BMI	mean (sd)	31.0 (8.0)	28.6 (5.8)	<0.01
Race				
American Indian/Alaska Native	n (%)	0 (0%)	6 (2.8%)	0.18
Asian	n (%)	3 (2.5%)	9 (4.3%)	
Native Hawaiian/Pacific Islander	n (%)	0 (0%)	0 (0%)	
Black/African American	n (%)	12 (10.1%)	11 (5.2%)	
White	n (%)	98 (82.4%)	172 (81.5%)	
More than one	n (%)	1 (0.8%)	5 (2.4%)	
Unknown/not reported	n (%)	4 (3.4%)	4 (1.9%)	
Ethnicity				
Hispanic	n (%)	4 (3.4%)	9 (4.3%)	0.82
Non-Hispanic	n (%)	92 (77.3%)	166 (78.7%)	
Unknown/not reported	n (%)	23 (19.3%)	36 (17.1%)	
Primary diagnosis				
Aplastic anemia	n (%)	4 (3.4%)	5 (2.4%)	0.01
Acute myeloid leukemia	n (%)	41 (34.5%)	110 (52.1%)	
Acute lymphoblastic leukemia	n (%)	10 (8.4%)	11 (5.2%)	
Chronic myelogenous leukemia	n (%)	4 (3.4%)	4 (1.9%)	
Chronic lymphocytic leukemia	n (%)	1 (0.8%)	1 (0.5%)	


Non-Hodgkin's lymphoma	n (%)	12 (10.1%)	17 (8.1%)	
Hodgkin's Lymphoma	n (%)	4 (3.4%)	8 (3.8%)	
Myelodysplastic syndrome	n (%)	11 (3.4%)	26 (2.4%)	
Myeloma	n (%)	13 (10.9%)	12 (5.7%)	
Myelofibrosis	n (%)	5 (4.2%)	12 (5.7%)	
Other	n (%)	14 (11.8%)	5 (2.4%)	
Therapeutic group				
Allogeneic transplant	n (%)	57 (47.9%)	71 (33.6%)	<0.01
Acute autologous transplant	n (%)	36 (30.3%)	36 (17.1%)	
Chemo/immunotherapy	n (%)	26 (21.8%)	104 (49.3%)	
Outcome				
WHO Grade 2+ bleeding		54 (45%)	152 (46%)	>0.99

Supplementary Table 1. Demographics comparison of FEAT participants with non-FEAT A-TREAT subjects.



Supplementary figure 1

Supplemental figure 1: Baseline tPA-challenged clot lysis times (tPA-CLT) in FEAT participants compared to normal controls (NCs).



Supplementary figure 2

Supplemental figure 2: Correlation matrices between measured fibrinolysis parameters at baseline and trough study drug levels. In red – Spearman’s r correlation coefficient between all baseline fibrinolysis parameters. In green – Spearman’s r correlation coefficient between placebo treated trough level fibrinolysis parameters. In blue – Spearman’s r correlation coefficient between TXA treated trough level fibrinolysis parameters.